Serogroup A Neisseria meningitidis with reduced susceptibility to ciprofloxacin

Emerging Infectious Diseases

Volumn 14, Issue 10, 2008, Pages 1667-1669

  Strahilevitz, Jacob ^a   Adler, Amos ^a   Smollan, Gillian ^b   Temper, Violeta ^a   Keller, Nathan ^b   Block, Colin ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA; DNA POLYMERASE; DNA TOPOISOMERASE; GYRASE INHIBITOR;

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD GROUP TYPING; CHROMOSOME; DEMOGRAPHY; DISEASE ASSOCIATION; ESCHERICHIA COLI; LETTER; MENINGOCOCCOSIS; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; CIPROFLOXACIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; HUMANS; ISRAEL; MENINGOCOCCAL INFECTIONS; MUTATION; NEISSERIA MENINGITIDIS; SEROTYPING;

EID: 54249116740     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1410.080252     Document Type: Letter

References (10)

1. Singhal S, Purnapatre KP, Kalia V, Dube S, Nair D, Deb M, et al. Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerg Infect Dis. 2007;13:1614-6.
2. Centers for Diseases Control and Prevention. Emergence of fluoroquinolone-resistant Neisseria meningitidis - Minnesota and North Dakota, 2007-2008. MMWR Morb Mortal Wkly Rep. 2008;57:173-5.
3. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. qnr Prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother. 2006;50:2872-4. DOI: 10.1128/AAC.01647-05
4. Jolley KA, Chan MS, Maiden MC. mlst-dbNet-distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics. 2004;5:86. DOI: 10.1186/1471-2105-5-86
5. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 18th informational supplement. CLSI document M100-S18. Wayne (PA): The Institute; 2008.
6. Hooper DC, Rubinstein E. Mechanisms of quinolone resistance. Quinolone antimicrobial agents. 3rd ed. Washington: American Society for Microbiology Press; 2003. p. 41.
7. Bagel S, Hullen V, Wiedemann B, Heisig P. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother. 1999;43:868.
8. Shafer WM, Veal WL, Lee EH, Zarantonelli L, Balthazar JT, Rouquette C. Genetic organization and regulation of antimicrobial efflux systems possessed by Neisseria gonorrhoeae and Neisseria meningitidis. J Mol Microbiol Biotechnol. 2001;3:219-24.
9. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Hye PC, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12:83. DOI: 10.1038/nm1347
10. Block C, Roitman M, Bogokowsky B, Meizlin S, Slater PE. Forty years of meningococcal disease in Israel: 1951-1990. Clin Infect Dis. 1993;17:126-32.